Holoclara is a technology company.
Holoclara has raised $16.0M across 1 funding round.
Holoclara has raised $16.0M in total across 1 funding round.
Holoclara has raised $16.0M in total across 1 funding round.
Holoclara's investors include AlleyCorp, Bold Capital Partners, Aniq Kassam, Lorie&co, Third Sphere.
Holoclara is a biotechnology company developing safe, orally available therapies derived from gut roundworms (nematodes) to treat allergic and autoimmune diseases, such as asthma, type 1 diabetes, and inflammatory bowel disease (IBD).[1][2][4] It serves patients with these historically untreatable conditions by mining immunomodulatory molecules from worms, leveraging the hygiene hypothesis that worm presence historically protected against autoimmunity.[1][2] The company has raised $16 million in Series A financing led by BOLD Capital Partners, with participation from Horizons Ventures and angels, fueling preclinical advancement and a Phase 1 program started November 2024.[1][5]
Founded and led by physician-scientist Andrea Choe, Holoclara builds on decades of preclinical data showing worm-derived molecules' efficacy in calming immune responses.[1] The idea stems from the hygiene hypothesis: regions with intestinal roundworms had lower autoimmune rates until worm eradication in the 1900s coincided with disease rises, suggesting symbiotic co-evolution where worms produced protective secretions to evade immunity.[2][6] Early traction includes mouse model successes for asthma, type 1 diabetes, and IBD, backed by a team of worm biology and biotech experts, culminating in the 2024 Series A to translate this "longest-running drug program in history" into human therapies.[1][2][6]
Holoclara rides the autoimmune disease wave, addressing a market exploding due to modern hygiene, aging populations, and lifestyle shifts that fuel allergies and autoimmunity.[1][2] Timing aligns with advances in synthetic biology and immunomodulation, where worm-inspired therapies offer oral alternatives to injectables like biologics.[3][6] Favorable forces include rising unmet need (millions affected globally) and investor interest in bio-inspired platforms, positioning Holoclara to influence the ecosystem by validating nematode chemistry for broader applications beyond its initial indications.[1][4]
Holoclara's Phase 1 entry signals momentum toward first-in-class worm-derived drugs, with preclinical wins de-risking human proof.[5] Upcoming milestones include trial data readouts and potential expansion to metabolic/inflammatory targets, shaped by trends in precision immunomodulation and AI-accelerated drug discovery.[6] Its influence could grow by pioneering "symbiont-derived" biotech, challenging hygiene hypothesis skeptics and unlocking worm platforms for pharma giants—echoing how mRNA tech transformed vaccines, but for chronic immunity.
Holoclara has raised $16.0M across 1 funding round. Most recently, it raised $16.0M Series A in June 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2024 | $16.0M Series A | AlleyCorp, Bold Capital Partners, Aniq Kassam, Lorie&co, Third Sphere |